Deakin University
Browse

File(s) under embargo

Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests

journal contribution
posted on 2024-05-07, 04:22 authored by Alex Bahar-FuchsAlex Bahar-Fuchs, V Villemagne, K Ong, G Chetélat, F Lamb, CB Reininger, M Woodward, CC Rowe
Assessment of disease biomarkers, particularly the in vivo assessment of amyloid-β (Aβ) burden with positron emission tomography (PET), is gradually becoming central to the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease (AD). However, the incorporation of biomarker evidence to the diagnostic process is currently restricted mainly to research settings. The identification of memory measures that are associated with Aβ is of clinical relevance as this may enhance the confidence in making a diagnosis of MCI due to AD in clinical settings. Forty one persons with amnestic MCI underwent Aβ imaging with 18F-Florbetaben PET, magnetic resonance imaging, and a comprehensive neuropsychological assessment. All measures of episodic memory were significantly correlated with Aβ burden, but regression analyses revealed a strong and selective association between story recall and Aβ over and beyond the effects of age, education, global cognition, hippocampal volume, or other memory tests. Analyses of sensitivity and specificity of memory measures to detect high versus low Aβ scans suggested that word-list recall performed better when high sensitivity was preferred, whereas story recall performed better when high specificity was preferred. In conclusion, a measure of story recall may increase the confidence in making a diagnosis of MCI due to AD in clinical settings. © 2013 - IOS Press and the authors. All rights reserved.

History

Journal

Journal of Alzheimer's Disease

Volume

33

Pagination

451-462

Location

Netherlands

ISSN

1387-2877

eISSN

1875-8908

Language

English

Publication classification

C1.1 Refereed article in a scholarly journal

Issue

2

Publisher

IOS PRESS